Citizens JMP Initiates IDEAYA Biosciences (IDYA) With a Buy Rating

Group 1 - IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is recognized as one of the best stocks to buy for the next three months according to hedge funds, with a price target of $41 set by Citizens JMP analyst Ivan Tuerkcan [1] - The company has initiated a Phase 1/2 clinical trial for a combination therapy involving IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy, targeting non-small cell lung cancer (NSCLC) patients with MTAP deletion [2][3] - The trial initially focused on MTAP-deletion urothelial cancer but expanded to include NSCLC in April 2025, conducted in collaboration with Gilead Sciences, which supplies Trodelvy [3]